1-[1-(biphenyl-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one | 844685-96-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[1-(biphenyl-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
• 英文别名: 1-[1-(4-phenylphenyl)sulfonylpiperidin-4-yl]-4H-3,1-benzoxazin-2-one
• CAS: 844685-96-7
• 化学式: C₂₅H₂₄N₂O₄S
• 分子量: 448.543
• InChiKey: UQFSCZNHSCTTRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  75.3
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• [EN] ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY<br/>[FR] COMBINAISON DE SUBSTANCES ACTIVES COMPORTANT UN COMPOSE A AFFINITE DE RECEPTEUR NPY ET UN COMPOSE A AFFINITE DE RECEPTEUR 5-HT6
  申请人：ESTEVE LABOR DR

  公开号：WO2005014000A1

  公开（公告）日：2005-02-17

  The present invention relates to an active substance combination comprising at least one compound with neuropeptide Y-receptor affinity and at least one compound with 5-HT6 receptor affinity, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.

  本发明涉及一种活性物质组合，包括至少一种具有神经肽Y受体亲和力的化合物和至少一种具有5-HT6受体亲和力的化合物，以及包含所述活性物质组合的药物和利用该活性物质组合制造药物的用途。
• Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity
  申请人：Torrens Jover Antoni

  公开号：US20070009597A1

  公开（公告）日：2007-01-11

  The present invention relates to an active substance combination comprising at least one compound with neuropeptide Y-receptor affinity, preferably neuropeptide Y5-receptor affinity, and at least one compound with 5-HT 6 receptor affinity, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.

  本发明涉及一种活性物质组合，包括至少一种具有神经肽Y受体亲和力的化合物，优选为神经肽Y5受体亲和力，以及至少一种具有5-HT6受体亲和力的化合物，一种包含该活性物质组合的药物，以及使用该活性物质组合制造药物。
• Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments
  申请人：Torrens Jover Antoni

  公开号：US20070032482A1

  公开（公告）日：2007-02-08

  The present invention relates to benzoxazinone-derived sulphonamide compounds of general formula (I), a process for their preparation, a medicament comprising these compounds and the use of benzoxazinone-derived sulphonamide compounds for the preparation of medicaments for 5-HT 6 receptor regulation as well as for the treatment of disorders related thereto.

  本发明涉及一般式(I)的苯并噁唑酮衍生磺酰胺化合物，其制备过程，包含这些化合物的药物以及苯并噁唑酮衍生磺酰胺化合物用于制备5-HT6受体调节剂药物以及治疗与之相关的疾病。
• ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY
  申请人：Torrens Jover Antoni

  公开号：US20120128768A1

  公开（公告）日：2012-05-24

  The present invention relates to an active substance combination comprising at least one compound with neuropeptide Y-receptor affinity and at least one compound with 5-HT6 receptor affinity, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.

  本发明涉及一种活性物质组合物，包括至少一种具有神经肽Y受体亲和力的化合物和至少一种具有5-HT6受体亲和力的化合物，以及包含该活性物质组合物的药物和使用该活性物质组合物制造药物的用途。
• CONJUGATE OF WATER-SOLUBLE MODIFIED HYALURONIC ACID AND GLP-1 ANALOGUE
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1857467A1

  公开（公告）日：2007-11-21

  To provide a GLP-1 analogue long-acting prophylactic or therapeutic agent for diabetes, diabetic complications and/or obesity due to diabetes which provides an extended half-life of a GLP-1 analogue in the blood to prevent frequent administration, and is biodegradable and safe. The present invention provides a conjugate obtained by binding, to a GLP-1 analogue into which a mercapto group is incorporated, water soluble hyaluronic acid modification product obtained by incorporating a substituent via an amide bond to the carboxyl group of glucuronic acid portion of hyaluronic acid as a derivative thereof, using a specific condensing agent in an aprotic polar solvent; and a prophylacitc or therapeutic agent having a durable blood glucose lowering effect for diabetes, diabetic complications or obesity.

  提供一种GLP-1类似物长效预防或治疗糖尿病、糖尿病并发症和/或糖尿病所致肥胖症的药物，该药物可延长GLP-1类似物在血液中的半衰期，避免频繁给药，并且可生物降解，安全可靠。 本发明提供了一种共轭物，该共轭物是通过在非沸腾极性溶剂中使用特定的缩合剂，在透明质酸的葡萄糖醛酸部分的羧基上通过酰胺键加入一个取代基而得到的水溶性透明质酸修饰产品，作为其衍生物，与加入了巯基的GLP-1类似物结合；以及一种对糖尿病、糖尿病并发症或肥胖症具有持久降血糖效果的亲和剂或治疗剂。